Anti-HER2 monoclonal antibodies (trastuzumab and pertuzumab) exert antitumor effects in HER2-positive breast cancer by blocking HER2 signaling and activating antibody-dependent cytotoxicity (ADCC) (43, 44). Here, ERBB2 is linked to breast cancer.